Skip to main content
. 2024 Feb 29;36(1):78–89. doi: 10.21147/j.issn.1000-9604.2024.01.08

Table 2. Clinicopathologic and molecular features of CLDN18.2-positive or negative (cut-off: 2+, 70%) GC patients.

Characteristics n (%) P
CLDN18.2-neg CLDN18.2-pos
CLDN18.2, claudin 18 isoform 2; GC, gastric cancer; EGJ, gastroesophageal junction; HER2, epidermal growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; amp, amplification; PD-L1, programmed death-ligand 1; CPS, combined positive score; EBV, Epstein-Barr virus; dMMR, mismatch repair-deficient; pMMR, mismatch repair-proficient; TMB, tumor mutational burden; muts, mutations; pos, positive; neg, negative.
Total 274 (51.1) 262 (48.9)
Age (year)
 <60 161 (58.8) 203 (78.1) <0.001
 ≥60 113 (41.2) 57 (21.9)
Sex
 Female 73 (26.8) 125 (47.7) <0.001
 Male 199 (73.2) 137 (52.3)
Histopathology
 EGJ 76 (28.1) 37 (14.6) <0.001
 Non-EGJ 194 (71.9) 217 (85.4)
Lauren
 Diffuse 74 (34.6) 115 (51.6) <0.001
 Intestinal 94 (43.9) 54 (24.2)
 Mixed 46 (21.5) 54 (24.2)
Differentiation
 High 2 (0.8) 3 (1.2) 0.023
 Moderate 61 (24.2) 36 (14.6)
 Poor 189 (75.0) 208 (84.2)
Metastasis site
 Liver 91 (29.0) 53 (16.6) <0.001
 Lung 33 (10.5) 18 (5.6) 0.024
 Peritoneum 150 (47.8) 171 (53.4) 0.154
 Uterine adnexa 26 (8.3) 64 (20.0) <0.001
 Lymph node 14 (4.5) 14 (4.4) 0.959
HER2 status
 Negative 215 (85.0) 233 (94.0) 0.001
 Positive 38 (15.0) 15 (6.0)
  IHC 2+ FISH
  amp
12 (31.60) 5 (33.3) 0.902
  IHC 3+ 26 (68.40) 10 (66.7)
PD-L1 status
 CPS<1 128 (51.8) 157 (65.1) 0.003
 CPS≥1 119 (48.2) 84 (34.9)
 CPS<5 168 (68.0) 189 (78.4) 0.009
 CPS≥5 79 (32.0) 52 (21.6)
 CPS<10 191 (77.6) 210 (87.1) 0.006
 CPS≥10 55 (22.4) 31 (12.9)
EBV status
 Negative 203 (99.5) 200 (97.6) 0.101
 Positive 1 (0.5) 5 (2.4)
MMR status
 dMMR 3 (0.9) 4 (1.7) 0.420
 pMMR 230 (99.1) 231 (98.3)
TMB (muts/Mb)
 TMB<10 46 (78.0) 50 (83.3) 0.458
 TMB≥10 13 (22.0) 10 (16.7)